Pharming Group (CHIX:PHARMA) Cyclically Adjusted PB Ratio: (As of Aug. 01, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:PHARMA Pharming Group CHIX:PHARMA
70 GF Score
Price €0.85
GF Value €1.07
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Pharming Group Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pharming Group  (CHIX:PHARMa) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Pharming Group Cyclically Adjusted PB Ratio Related Terms


Pharming Group Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Pharming Group's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharming Group Cyclically Adjusted PB Ratio Chart

Pharming Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.15 8.43 6.42 4.82 6.48

Pharming Group Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.43 5.80 6.48 6.26 0.00

CHIX:PHARMA vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Pharming Group's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharming Group Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Pharming Group's Cyclically Adjusted PB Ratio falls into.


CHIX:PHARMA
70GF Score
Pharming Group CHIX:PHARMA
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharming Group Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Pharming Group's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Pharming Group's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.311/138.6000*138.6000
=0.311

Current CPI (Jun. 2026) = 138.6000.

Pharming Group Quarterly Data

Book Value per Share CPI Adj_Book
201609 0.036 100.570 0.050
201612 0.060 100.710 0.083
201703 0.063 101.440 0.086
201706 0.014 101.370 0.019
201709 0.011 102.030 0.015
201712 0.028 101.970 0.038
201803 0.055 102.470 0.074
201806 0.066 103.100 0.089
201809 0.077 103.950 0.103
201812 0.100 103.970 0.133
201903 0.110 105.370 0.145
201906 0.125 105.840 0.164
201909 0.142 106.700 0.184
201912 0.167 106.800 0.217
202003 0.181 106.850 0.235
202006 0.200 107.510 0.258
202009 0.213 107.880 0.274
202012 0.236 107.850 0.303
202103 0.242 108.870 0.308
202106 0.255 109.670 0.322
202109 0.254 110.790 0.318
202112 0.263 114.010 0.320
202203 0.272 119.460 0.316
202206 0.290 119.050 0.338
202209 0.308 126.890 0.336
202212 0.294 124.940 0.326
202303 0.284 124.720 0.316
202306 0.281 125.830 0.310
202309 0.293 127.160 0.319
202312 0.299 126.450 0.328
202403 0.281 128.580 0.303
202406 0.303 129.910 0.323
202409 0.299 131.610 0.315
202412 0.310 131.630 0.326
202503 0.289 133.330 0.300
202506 0.303 133.960 0.313
202509 0.324 135.920 0.330
202512 0.337 135.270 0.345
202603 0.329 136.910 0.333
202606 0.311 138.600 0.311

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Pharming Group (CHIX:PHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of €0.85 is trading 20.7% below its estimated GF Value™ of €1.07. GuruFocus considers Pharming Group to be Modestly Undervalued.

Key valuation signals for CHIX:PHARMA:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: €1.07 vs. price of €0.85 (20.7% below fair value)
  • GF Score™: 70/100 with 2 warning signs

No single metric tells the full story. See the CHIX:PHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
70GF Score

Get the complete analysis for CHIX:PHARMA

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.85
Price
€1.07
GF Value